

Guidelines on compounding of medicines review - response template

The Pharmacy Board of Australia is inviting feedback on its draft revised *Guidelines for compounding of medicines* (the draft revised guidelines). Optional questions have been provided below and you may wish to address some or all of these in your response.

Published submissions will include the names (if provided) of the individuals and/or organisations making the submission unless confidentiality is requested.

Do you want your responses to be published after public consultation?

- Yes, I want my responses to be published after public consultation
- No, I do not want my responses to be published after public consultation

Submissions for website publication should be sent in Word format or equivalent.¹

Name: ___Stephen Furlan (National Compounding Manager) _____

Organisation: HPS Pharmacies _____

Contact email: [REDACTED] _____

Please note this response template contains the same questions as the online survey. Please choose only ONE method of responding to avoid duplicating your submission.

¹ We aim to publish documents in accessible formats (such as word files) to meet international website accessibility guidelines. Therefore, while you are welcome to supply a PDF file of your feedback, we ask that you also provide a text or word file. More information about this is available at <https://www.ahpra.gov.au/About-Ahpra/Accessibility.aspx>

	Question	Your feedback (include guideline number/section)
1	<p>The revised compounding guidelines include additional content on medicine supply pathways to consider before deciding if it is appropriate to compound a medicine (Guideline 1 When to compound medicines).</p> <p>Is the new content on medicine supply pathways clear and helpful? Why or why not?</p>	
2	<p>The compounding guidelines advise that a copy of the formula for their compounded medicine (listing all active ingredients and their strengths, and all inactive ingredients) must be provided to the patient when requested (Guideline 13 Supporting informed patient choice). Providing patients with information about the ingredients in their compounded medicine will support patient choice and safer patient outcomes.</p> <p>Do you agree that the formula for their compounded medicine must be provided when requested by the patient? Why or why not?</p>	
3	<p>The revised compounding guidelines include content that is specific to medicines compounded for animal patients.</p> <p>Is the new content that is specific to medicines for animal patients clear and helpful? Why or why not?</p>	
4	<p>Is there any content that needs to be changed, added or deleted in the revised guidelines? If so, please provide your suggestions and reasons.</p>	<p><i>With 3.1 Sterile medicines, rather than being required to adhere to only one of the 3 guides/standards, a pharmacy should be able to utilise one or more of these standards depending on the relevant aspects of the standard applicable to the pharmacy practice to ensure best practice and that aspects not covered in a single guide/standard are be addressed.</i></p>

	Question	Your feedback (include guideline number/section)
5	<p>Is the language of the revised guidelines clear and is the structure helpful? Why or why not?</p>	
6	<p>Please provide any other feedback about the revised guidelines.</p>	
7	<p>The Board proposes to retire the <i>Professional practice profile</i> for pharmacists undertaking complex compounding, as a professional practice profile should be practitioner specific, describe an individual's scope of practice and is not common to all pharmacists undertaking complex compounding. Individuals should develop their own practice profile by selecting the relevant competencies from the competency standards and customising them for use in their own practice setting.</p> <p>Do you agree with the Board's proposal to retire the currently published <i>Professional practice profile</i> for pharmacists undertaking complex compounding? Why or why not?</p>	
8	<p>The Board developed the fact sheet to provide helpful context for members of the public and support their participation in this consultation.</p> <p>Should the Board publish the fact sheet on its website for pharmacists and members of the public to access? Why or why not?</p>	